Related Experiment Video
Updated: Dec 30, 2025
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
Published on: January 20, 2019
Clinical prognostic implications of EPB41L4A expression in multiple myeloma
Weilong Zhang1, Rui Lai2,3, Xue He4
1Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Abstract:
Background: Multiple myeloma (MM) is one of the most common incurable malignancies in malignant plasma cell disease. EPB41L4A is a target gene for the Wnt/β-catenin pathway, which is closely related to the survival of multiple myeloma cells. However, there is currently no research report on the prognostic significance of the EPB41L4A gene in MM. Methods: We studied the biological significance and prognostic significance of EPB41L4A expression in MM by integrating 1956 MM samples from 7 datasets, and explored the relationship between EPB41L4A expression and MM ISS stage, molecular type, therapeutic response and survival. Results: We found that the expression level of EPB41L4A is inversely proportional to the copy number of 1q21 (P = 3.4e-13). EPB41L4A was low expressed in MAF, MMSET and proliferating molecular typing patients (P <= 0.001). High expression of EPB41L4A can predict good survival in MM (EFS: P < 0.0001; OS: P < 0.0001). We found that patients with relapsed MM had lower expression levels of EPB41L4A than those without recurrence (P = 0.0039). We also found that EPB41L4A can predict the prognosis of MM patients may be related to DNA replication. These results indicate that the initial expression level of EPB41L4A can predict the prognosis of MM patients. Conclusions: We found that the high expression of EPB41L4A predicts good survival level in MM.
Insights
High expression of the EPB41L4A gene indicates a good prognosis for multiple myeloma (MM) patients. This finding suggests EPB41L4A may serve as a valuable prognostic biomarker in MM, potentially linked to DNA replication processes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Multiple myeloma (MM) is a prevalent, incurable plasma cell malignancy.
- The Wnt/β-catenin pathway influences MM cell survival, with EPB41L4A as a key target gene.
- The prognostic role of EPB41L4A in MM remains unexplored.
Purpose of the Study:
- To investigate the biological and prognostic significance of EPB41L4A expression in MM.
- To explore correlations between EPB41L4A levels and MM clinical parameters.
- To assess EPB41L4A as a predictive biomarker for MM patient outcomes.
Main Methods:
- Integrated analysis of 1956 MM samples from 7 independent datasets.
- Examined EPB41L4A expression in relation to MM ISS stage, molecular subtypes, and therapeutic response.
- Correlated EPB41L4A expression with event-free survival (EFS) and overall survival (OS).
Main Results:
- EPB41L4A expression inversely correlated with 1q21 copy number (P = 3.4e-13).
- Lower EPB41L4A expression observed in MAF, MMSET, and proliferating molecular subtypes (P <= 0.001).
- High EPB41L4A expression significantly predicted favorable EFS (P < 0.0001) and OS (P < 0.0001).
- Relapsed MM patients exhibited lower EPB41L4A expression than non-relapsed patients (P = 0.0039).
- EPB41L4A's prognostic value may involve DNA replication pathways.
Conclusions:
- High EPB41L4A expression is a significant predictor of good survival in MM patients.
- EPB41L4A serves as a potential prognostic biomarker for MM.
- Further research into EPB41L4A's role in MM pathogenesis and prognosis is warranted.
